BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11040038)

  • 1. Oxaliplatin-induced damage of cellular DNA.
    Woynarowski JM; Faivre S; Herzig MC; Arnett B; Chapman WG; Trevino AV; Raymond E; Chaney SG; Vaisman A; Varchenko M; Juniewicz PE
    Mol Pharmacol; 2000 Nov; 58(5):920-7. PubMed ID: 11040038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.
    Faivre S; Chan D; Salinas R; Woynarowska B; Woynarowski JM
    Biochem Pharmacol; 2003 Jul; 66(2):225-37. PubMed ID: 12826265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.
    Woynarowski JM; Chapman WG; Napier C; Herzig MC; Juniewicz P
    Mol Pharmacol; 1998 Nov; 54(5):770-7. PubMed ID: 9804612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
    Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
    Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
    Kasparkova J; Vojtiskova M; Natile G; Brabec V
    Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
    Malina J; Natile G; Brabec V
    Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription inhibition by platinum-DNA cross-links in live mammalian cells.
    Ang WH; Myint M; Lippard SJ
    J Am Chem Soc; 2010 Jun; 132(21):7429-35. PubMed ID: 20443565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
    Pang SK; So WK; Ho YP; Au-Yeung CF
    Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein interactions with platinum-DNA adducts: from structure to function.
    Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
    J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
    Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
    Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
    Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
    J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity and DNA damage induced by a new platinum(II) complex with pyridine and dithiocarbamate.
    Marzano C; Fregona D; Baccichetti F; Trevisan A; Giovagnini L; Bordin F
    Chem Biol Interact; 2002 Aug; 140(3):215-29. PubMed ID: 12204578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
    Lovejoy KS; Serova M; Bieche I; Emami S; D'Incalci M; Broggini M; Erba E; Gespach C; Cvitkovic E; Faivre S; Raymond E; Lippard SJ
    Mol Cancer Ther; 2011 Sep; 10(9):1709-19. PubMed ID: 21750216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: the role of low-energy electrons.
    Rezaee M; Hunting DJ; Sanche L
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):847-53. PubMed ID: 23910707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.